These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 28195647)

  • 41. Pathology of upper tract urothelial carcinoma with emphasis on staging.
    Mazzucchelli R; Scarpelli M; Galosi AB; Di Primio R; Lopez-Beltran A; Cheng L; Montironi R
    Int J Immunopathol Pharmacol; 2014; 27(4):509-16. PubMed ID: 25572730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and molecular characteristics of bladder urothelial carcinoma subtypes.
    Li Y; Yang K; Li K; Liu H; Zhao S; Jiao M; Fu X
    J Cell Biochem; 2019 Jun; 120(6):9956-9963. PubMed ID: 30548659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene expression profiling of noninvasive primary urothelial tumours using microarrays.
    Aaboe M; Marcussen N; Jensen KM; Thykjaer T; Dyrskjøt L; Orntoft TF
    Br J Cancer; 2005 Nov; 93(10):1182-90. PubMed ID: 16265353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer.
    Bui TD; O'Brien T; Crew J; Cranston D; Harris AL
    Br J Cancer; 1998; 77(2):319-24. PubMed ID: 9461004
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.
    Eriksson P; Sjödahl G; Chebil G; Liedberg F; Höglund M
    Oncotarget; 2017 Jul; 8(30):48905-48914. PubMed ID: 28388586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.
    Marín-Aguilera M; Mengual L; Ribal MJ; Ars E; Ríos J; Gázquez C; Villavicencio H; Alcaraz A
    Urology; 2012 Jan; 79(1):240.e9-15. PubMed ID: 22055693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
    McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
    Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo-/radio-resistance by suppressing caspase-mediated apoptosis.
    Yu CC; Li CF; Chen IH; Lai MT; Lin ZJ; Korla PK; Chai CY; Ko G; Chen CM; Hwang T; Lee SC; Sheu JJ
    J Pathol; 2019 Aug; 248(4):476-487. PubMed ID: 30945298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chloride Intracellular Channel Protein 1 (CLIC1) Ιs Over-expressed in Muscle Invasive Urinary Bladder Cancer.
    Adelmann TG; Camerota TC; Ceausu AR; Cimpean AM; Mazzanti M; Raica M
    Anticancer Res; 2020 Dec; 40(12):6879-6884. PubMed ID: 33288580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
    Jin N; Jin X; Gu X; Na W; Zhang M; Zhao R
    Mol Med Rep; 2015 Aug; 12(2):3170-6. PubMed ID: 25955758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A molecular taxonomy for urothelial carcinoma.
    Sjödahl G; Lauss M; Lövgren K; Chebil G; Gudjonsson S; Veerla S; Patschan O; Aine M; Fernö M; Ringnér M; Månsson W; Liedberg F; Lindgren D; Höglund M
    Clin Cancer Res; 2012 Jun; 18(12):3377-86. PubMed ID: 22553347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.
    Rinaldetti S; Wirtz RM; Worst TS; Eckstein M; Weiss CA; Breyer J; Otto W; Bolenz C; Hartmann A; Erben P
    Oncotarget; 2017 Jul; 8(29):47595-47606. PubMed ID: 28498805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The molecular basis of breast cancer pathological phenotypes.
    Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
    J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Translational control of aberrant stress responses as a hallmark of cancer.
    El-Naggar AM; Sorensen PH
    J Pathol; 2018 Apr; 244(5):650-666. PubMed ID: 29293271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of vascular endothelial growth factors A, C and D as indicators of lymphangiogenesis and angiogenesis in invasive and non-invasive urothelial carcinoma bladder.
    Khadim MT; Ahmed SA; Khan FA; Ikram A; Shaikh SY
    J Pak Med Assoc; 2015 Aug; 65(8):851-6. PubMed ID: 26228330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis.
    Xiong J; Xiong K; Bing Z
    Cancer Biomark; 2018 Feb; 21(3):535-546. PubMed ID: 29226853
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.